Citadel Advisors
CTXR icon

Citadel Advisors’s Citius Pharmaceuticals CTXR Stock Holding History

Citadel Advisors’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$2 – 14624
2024
Q4 		$4 Buy
+1
New +$7 ﹤0.01% 14402
2024
Q3 		– Sell
-7,425
Closed -$125K – 14360
2024
Q2 		$108K Buy
+7,425
New +$133K ﹤0.01% 10808
2023
Q4 		– Sell
-194
Closed -$3.68K – 14385
2023
Q3 		$3.32K Buy
194
+163
+526% +$3.87K ﹤0.01% 13598
2023
Q2 		$944 Sell
31
-3,461
-99% -$114K ﹤0.01% 14015
2023
Q1 		$102K Sell
3,492
-12,195
-78% -$352K ﹤0.01% 11233
2022
Q4 		$310K Buy
15,687
+11,432
+269% +$312K ﹤0.01% 9244
2022
Q3 		$129K Sell
4,255
-5,180
-55% -$142K ﹤0.01% 10858
2022
Q2 		$217K Buy
9,435
+4,954
+111% +$136K ﹤0.01% 10526
2022
Q1 		$200K Sell
4,481
-1,044
-19% -$41.2K ﹤0.01% 11540
2021
Q4 		$213K Buy
5,525
+910
+20% +$41.3K ﹤0.01% 11721
2021
Q3 		$234K Sell
4,615
-3,753
-45% -$188K ﹤0.01% 11620
2021
Q2 		$728K Buy
8,368
+7,248
+647% +$436K ﹤0.01% 9167
2021
Q1 		$50K Buy
1,120
+364
+48% +$14.5K ﹤0.01% 12897
2020
Q4 		$19K Buy
+756
New +$19.7K ﹤0.01% 10785
2020
Q3 		– Sell
-697
Closed -$20K – 10150
2020
Q2 		$20K Buy
697
+271
+64% +$5.93K ﹤0.01% 9549
2020
Q1 		$6K Buy
+426
New +$9K ﹤0.01% 9471
2019
Q2 		– Sell
-1,063
Closed -$38K – 9254
2019
Q1 		$38K Buy
+1,063
New +$31.3K ﹤0.01% 8918

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citadel Advisors's CTXR Position: Q1 2025 in Review

Citadel Advisors sold out of Citius Pharmaceuticals (CTXR) in Q1 2025, closing a stake of 1 share — an estimated $2 sold.

Citadel Advisors first reported a position in CTXR in Q1 2019 and held it in 17 quarters. The position peaked at $728K in Q2 2021. 28 funds tracked by Wall St. Rank hold CTXR as of Q1 2025.

  • Citadel Advisors reported no remaining Citius Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Citadel Advisors sold 1 Citius Pharmaceuticals share in Q1 2025, an estimated $2.
  • Citadel Advisors first reported a position in Citius Pharmaceuticals in Q1 2019 and held it in 17 quarters.
  • Citadel Advisors's Citius Pharmaceuticals position peaked at $728K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.